News
argenx's Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
R&D
Changing Faces: Pharma and biotech hires, September 2026
There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry’s biggest names.
News
Chemistry Nobel goes to molecular chirality researchers
The Nobel Prize in Chemistry 2026 has been awarded to Henri B Kagan and Kensō Soai for their discoveries in asymmetric organic synthesis.
News
Biohub raises $1.8bn for its 'virtual biology' initiative
Just months after launching an open-source 'virtual biology' platform, Biohub has raised $1.8 billion in backing for the AI-powered initiative.
News
European biotech leaders say optimism is returning
Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
